Lemaitre Vascular INC: management transactions · United States · SEC (Form 4)

About Lemaitre Vascular INC

LeMaitre Vascular, Inc. (ticker: LMAT) is a U.S.-based medical device company listed on the NASDAQ in the United States and focused on peripheral vascular disease. The company is headquartered in Burlington, Massachusetts. It was founded in 1983 by vascular surgeon George D. LeMaitre, and its long-standing strategy has been to serve a narrowly defined but clinically important market: tools, implants, and services used by vascular surgeons to treat arterial and venous disease, especially complex cases where standard solutions may be less effective. LeMaitre operates as a specialist rather than a broad-based medtech conglomerate. Its portfolio includes valvulotomes, carotid shunts, embolectomy and occlusion catheters, biologic and cardiac patches, biologic and synthetic vascular and dialysis grafts, anastomotic clips, and radiopaque tape. In practical terms, the company sells products used in vascular surgery, dialysis access, lower-extremity bypass, carotid procedures, and related interventions. This focus gives LeMaitre a differentiated position with surgeons and hospitals that value procedure-specific solutions, clinical performance, and consistent product availability. From a competitive standpoint, LeMaitre benefits from being a niche leader in a highly specialized segment of the medical device market. Its commercial model is built around direct relationships with surgeons and hospital systems, supported by a global distribution footprint. The company describes itself as reaching more than 90 countries, with operations across North America, Europe, and Asia-Pacific. It also maintains regional infrastructure outside the United States, including a European headquarters in Germany and an Asia-Pacific headquarters in Singapore, which supports broader international penetration and local market access. Recent developments have remained supportive of the company’s growth narrative. LeMaitre has continued to expand through both product innovation and acquisitions. A notable acquisition was Artegraft, which broadened the company’s biologic and dialysis-access offering and strengthened its position in access-related vascular procedures. More recently, 2025 earnings releases showed continued sales growth, with stronger performance in catheters and grafts, alongside improved gross margin and operating leverage. Management also indicated that the international rollout of Artegraft is progressing ahead of plan. For equity investors, LMAT stands out as a focused, profitable niche medtech company with durable exposure to structural demand in vascular care, particularly in the United States and abroad.